ClinConnect ClinConnect Logo
Search / Trial NCT06231160

Clinical Comparative Study of Systematic Therapy Combined With MWA and Systematic Therapy for Pancreatic Cancer

Launched by CHINESE PLA GENERAL HOSPITAL · Jan 21, 2024

Trial Information

Current as of July 03, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for pancreatic cancer, which is known to be a very challenging disease to treat. The researchers want to find out if combining microwave ablation, a method that uses heat to destroy cancer cells, with standard therapy can be more effective and safe for patients with pancreatic cancer that cannot be surgically removed. Currently, less than 20% of pancreatic cancer patients can have surgery, and many experience a return of the disease within two years. This trial aims to explore whether this combination treatment can help more patients.

To participate in this trial, individuals need to be between the ages of 18 and 80 and have a clear diagnosis of inoperable pancreatic cancer. Potential participants should also have a performance status score that indicates they are relatively well despite their illness. However, people with serious heart, lung, liver, or kidney issues, or those with active infections or psychological problems that could affect their participation, will not be eligible. As the trial is not yet recruiting, participants can expect more information on what the treatment involves and how it will be monitored when they are approached. This study could pave the way for better treatment options for those facing this difficult condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Inoperable pancreatic cancer
  • Age from 18 to 80
  • PS score from 0 to 3
  • Clear pathological diagnosis
  • Exclusion Criteria:
  • Severe coagulation dysfunction
  • Individuals with severe heart, lung, liver, and kidney dysfunction
  • Individuals with acute or active infectious lesions in any part of the body
  • Researchers believe that there are any other factors that are not suitable for inclusion or that affect the participation of participants in the study
  • Psychological health issues that hinder this experiment

About Chinese Pla General Hospital

The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.

Locations

Patients applied

0 patients applied

Trial Officials

Ping Liang

Study Chair

The Fifth Medical Center of the General Hospital of the PLA of China

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported